Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1956 1
1975 3
1976 3
1977 3
1978 6
1979 4
1980 8
1981 6
1982 5
1983 8
1984 9
1985 8
1986 6
1987 9
1988 24
1989 13
1990 13
1991 16
1992 25
1993 20
1994 15
1995 19
1996 27
1997 33
1998 39
1999 39
2000 32
2001 50
2002 39
2003 39
2004 46
2005 54
2006 46
2007 52
2008 60
2009 58
2010 61
2011 67
2012 84
2013 82
2014 97
2015 87
2016 108
2017 115
2018 95
2019 108
2020 129
2021 135
2022 115
2023 95
2024 55

Text availability

Article attribute

Article type

Publication date

Search Results

2,048 results

Results by year

Filters applied: . Clear all
Page 1
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse.
Dimopoulos M, Weisel K, Moreau P, Anderson LD Jr, White D, San-Miguel J, Sonneveld P, Engelhardt M, Jenner M, Corso A, Dürig J, Pavic M, Salomo M, Casal E, Srinivasan S, Yu X, Nguyen TV, Biyukov T, Peluso T, Richardson P. Dimopoulos M, et al. Among authors: moreau p. Leukemia. 2021 Jun;35(6):1722-1731. doi: 10.1038/s41375-020-01021-3. Epub 2020 Sep 7. Leukemia. 2021. PMID: 32895455 Free PMC article. Clinical Trial.
Second-line PVd significantly improved PFS vs Vd in lenalidomide-refractory (17.8 vs 9.5 months; P = 0.0276) and lenalidomide-nonrefractory patients (22.0 vs 12.0 months; P = 0.0491), patients with prior bortezomib (17.8 vs 12.0 months; P = 0.0068), and patie …
Second-line PVd significantly improved PFS vs Vd in lenalidomide-refractory (17.8 vs 9.5 months; P = 0.0276) and lenalidomide-nonrefr …
Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma.
Mateos MV, Chari A, Usmani SZ, Goldschmidt H, Weisel K, Qi K, Londhe A, Nair S, Lin X, Pei L, Ammann E, Kobos R, Smit J, Parekh T, Marshall A, Slavcev M, Moreau P. Mateos MV, et al. Among authors: moreau p. Clin Lymphoma Myeloma Leuk. 2023 May;23(5):385-393. doi: 10.1016/j.clml.2023.02.006. Epub 2023 Mar 3. Clin Lymphoma Myeloma Leuk. 2023. PMID: 36967244 Clinical Trial.

In the primary analysis, outcomes were significantly improved with teclistamab versus PC: ORR (OR [95% CI] 4.81 [3.04-7.72]; P < .0001); VGPR rate (OR, 12.07 [6.91-22.11]; P < .0001); OS (HR, 0.54 [0.40-0.73]; P < .0001); PFS (HR, 0.59 [0.46-0.78];

…

In the primary analysis, outcomes were significantly improved with teclistamab versus PC: ORR (OR [95% CI] 4.81 [3.04-7.72]; P < .

…
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.
Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, Offidani M, McCarthy P, Evangelista A, Lonial S, Zweegman S, Musto P, Terpos E, Belch A, Hajek R, Ludwig H, Stewart AK, Moreau P, Anderson K, Einsele H, Durie BG, Dimopoulos MA, Landgren O, San Miguel JF, Richardson P, Sonneveld P, Rajkumar SV. Palumbo A, et al. Among authors: moreau p. Blood. 2015 Mar 26;125(13):2068-74. doi: 10.1182/blood-2014-12-615187. Epub 2015 Jan 27. Blood. 2015. PMID: 25628469 Free PMC article.

The 3-year overall survival was 84% in fit, 76% in intermediate-fitness (hazard ratio [HR], 1.61; P = .042), and 57% in frail (HR, 3.57; P < .001) patients. The cumulative incidence of grade 3 nonhematologic adverse events at 12 months was 22.2% in fit, 26.4% in

…
The 3-year overall survival was 84% in fit, 76% in intermediate-fitness (hazard ratio [HR], 1.61; P = .042), and 57% in frail (HR, 3. …
Comparison of 2 Methods for Estimating Multiple Sclerosis-Related Mortality.
Rollot F, Uhry Z, Dantony E, Vukusic S, Debouverie M, Le Page E, Ciron J, Ruet A, De Sèze J, Zéphir H, Labauge P, Defer G, Lebrun-Frenay C, Moreau T, Laplaud DA, Berger E, Clavelou P, Pelletier J, Thouvenot E, Heinzlef O, Camdessanche JP, Fauvernier M, Remontet L, Leray E. Rollot F, et al. Among authors: moreau t. Neurology. 2023 Dec 12;101(24):e2483-e2496. doi: 10.1212/WNL.0000000000207925. Epub 2023 Oct 12. Neurology. 2023. PMID: 37827849
Our objective was to contrast 2 frameworks to estimate probabilities of death attributed to MS (P(MS)) and other causes (P(other)): the cause-specific framework (CSF), which requires the causes of death, and the excess mortality framework (EMF), which does not. ...I …
Our objective was to contrast 2 frameworks to estimate probabilities of death attributed to MS (P(MS)) and other causes (P(oth …
Neutralization of extracellular histones by sodium-Β-O-methyl cellobioside sulfate in septic shock.
Garcia B, Su F, Dewachter L, Wang Y, Li N, Remmelink M, Eycken MV, Khaldi A, Favory R, Herpain A, Moreau A, Moiroux-Sahraoui A, Manicone F, Annoni F, Shi L, Vincent JL, Creteur J, Taccone FS. Garcia B, et al. Among authors: moreau a. Crit Care. 2023 Nov 24;27(1):458. doi: 10.1186/s13054-023-04741-x. Crit Care. 2023. PMID: 38001494 Free PMC article.

RESULTS: During the first 4 h, MAP remained > 65 mmHg in the early treatment group but decreased significantly in the others (p < 0.01 for interaction, median value at T4: (79 [70-90] mmHg for early treatment, 57 [70-90] mmHg for late treatment, and 55 [49-60] mmHg f

…
RESULTS: During the first 4 h, MAP remained > 65 mmHg in the early treatment group but decreased significantly in the others (p &l …
Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.
Einsele H, Moreau P, Bahlis N, Bhutani M, Vincent L, Karlin L, Perrot A, Goldschmidt H, van de Donk NWCJ, Ocio EM, Martinez-Lopez J, Rodríguez-Otero P, Dytfeld D, Diels J, Strulev V, Haddad I, Renaud T, Ammann E, Cabrieto J, Perualila N, Gan R, Zhang Y, Parekh T, Albrecht C, Weisel K, Mateos MV. Einsele H, et al. Among authors: moreau p. Adv Ther. 2024 Apr;41(4):1576-1593. doi: 10.1007/s12325-024-02797-x. Epub 2024 Feb 24. Adv Ther. 2024. PMID: 38402374 Free PMC article.

In adjusted comparisons, patients treated with talquetamab QW (n = 143) had significantly improved outcomes vs. RWPC; RRs were ORR 2.67, p < 0.0001; VGPR 4.70, p < 0.0001; CR 78.05, p = 0.0002; and HRs were PFS 0.52, p < 0.0001; TTNT 0.48,

…
In adjusted comparisons, patients treated with talquetamab QW (n = 143) had significantly improved outcomes vs. RWPC; RRs were ORR 2.67, …
Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.
Moreau P, Mateos MV, Gonzalez Garcia ME, Einsele H, De Stefano V, Karlin L, Lindsey-Hill J, Besemer B, Vincent L, Kirkpatrick S, Delforge M, Perrot A, van de Donk NWCJ, Pawlyn C, Manier S, Leleu X, Martinez-Lopez J, Ghilotti F, Diels J, Morano R, Albrecht C, Strulev V, Haddad I, Pei L, Kobos R, Smit J, Slavcev M, Marshall A, Weisel K. Moreau P, et al. Adv Ther. 2024 Feb;41(2):696-715. doi: 10.1007/s12325-023-02738-0. Epub 2023 Dec 19. Adv Ther. 2024. PMID: 38110653 Free PMC article.

Patients treated with teclistamab had significantly improved outcomes versus RWPC in LocoMMotion: ORR (RR [95% CI], 2.44 [1.79-3.33]; p < 0.0001), VGPR (RR 5.78 [3.74-8.93]; p < 0.0001), CR (RR 113.73 [15.68-825.13]; p < 0.0001), DOR (HR 0.39 [0.24-0

…
Patients treated with teclistamab had significantly improved outcomes versus RWPC in LocoMMotion: ORR (RR [95% CI], 2.44 [1.79-3.33]; p …
Serum ferritin distribution in elite athletes.
Nabhan D, Bielko S, Sinex JA, Surhoff K, Moreau WJ, Schumacher YO, Bahr R, Chapman RF. Nabhan D, et al. Among authors: moreau wj. J Sci Med Sport. 2020 Jun;23(6):554-558. doi: 10.1016/j.jsams.2019.12.027. Epub 2019 Dec 27. J Sci Med Sport. 2020. PMID: 31901316
RESULTS: SF distributions in male athletes were significantly lower than normal males aged 20 to <24yrs. (chi(2) 28.8, p<0.001) and aged 24 to <28yrs. (chi(2) 91.9, p<0.001). SF status was similar in female athletes and normal women aged 20 to <24yrs. …
RESULTS: SF distributions in male athletes were significantly lower than normal males aged 20 to <24yrs. (chi(2) 28.8, p<0.001) …
How Bacterial Adaptation to Cystic Fibrosis Environment Shapes Interactions Between Pseudomonas aeruginosa and Staphylococcus aureus.
Camus L, Briaud P, Vandenesch F, Moreau K. Camus L, et al. Among authors: moreau k. Front Microbiol. 2021 Mar 3;12:617784. doi: 10.3389/fmicb.2021.617784. eCollection 2021. Front Microbiol. 2021. PMID: 33746915 Free PMC article. Review.
Co-infection by the two species is a frequent situation that promotes their interaction. The ability of P. aeruginosa to outperform S. aureus has been widely described, and this competitive interaction was, for a long time, the only one considered. ...This review attempts …
Co-infection by the two species is a frequent situation that promotes their interaction. The ability of P. aeruginosa to outperform S …
Hyperbaric hyperoxemia as a risk factor for ventilator-acquired pneumonia?
Caplan M, Duburcq T, Moreau AS, Poissy J, Nseir S, Parmentier-Decrucq E. Caplan M, et al. Among authors: moreau as. PLoS One. 2021 Jun 23;16(6):e0253198. doi: 10.1371/journal.pone.0253198. eCollection 2021. PLoS One. 2021. PMID: 34161365 Free PMC article.
The occurrence of VAP was significantly associated with immunosuppression (p<0.029), MV duration (5 [3-7] vs 8 [5-11.5] days, p<0.0001), length of stay (8 [5-13] vs 19.5 [13-32] days, p<0.0001), reintubation (p<0.0001), intra-hospital trans …
The occurrence of VAP was significantly associated with immunosuppression (p<0.029), MV duration (5 [3-7] vs 8 [5-11.5] days, p …
2,048 results